🏛️ Verified NIH Record • Updated 2026-02-27

First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) (NCT05361395)

A Phase 1b Study Evaluating the Safety and Efficacy of First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung (DeLLphi-303)

🔵 Active, Not Recruiting Phase1 💊 Investigational Drug / Biologic Sponsor: Amgen

🩺 Plain-English Summary (8th-Grade Level)

This is a phase 1b study to assess the safety and tolerability of tarlatamab in combination with programmed death ligand (PD-L1) inhibition with and without chemotherapy.

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (7 items) and avoid the listed exclusions (14 items).

Location: University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Usually NOT eligible if any of the following apply:

  • Exclusion Criteria:
  • History of other malignancy within the past 2 years with exceptions.
  • Major surgery within 28 days of study day 1.
  • Untreated or symptomatic brain metastases and leptomeningeal disease.
  • Participants who experienced recurrent grade 2 pneumonitis or severe or life-threatening immune-mediated adverse events or infusion-related reactions including those that lead to permanent discontinuation while on treatment with immuno-oncology agents.
  • History of immune-related colitis.
  • History or evidence of interstitial lung disease or active, non-infectious pneumonitis.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment.
  • Participants with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment
  • Participant has known active infection requiring parenteral antibiotic treatment. Upon completion of parenteral antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint
  • NOTE: Simple urinary tract infections and uncomplicated bacterial pharyngitis are permitted if responding to an active treatment and after consultation with Medical Monitor. Participants requiring oral antibiotics who have been afebrile for \>24 hours, have no leukocytosis, nor clinical signs of infection are eligible. Screening for chronic infectious conditions is not required.
  • History of hypophysitis or pituitary dysfunction.

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (44 Sites)

Showing the first 25 of 44 sites.

  • University of Southern California, Norris Comprehensive Cancer Center — Los Angeles, California
  • Christiana Care Health Services — Newark, Delaware
  • Henry Ford Health System — Detroit, Michigan
  • Rutgers Cancer Institute of New Jersey — New Brunswick, New Jersey
  • New York University Grossman School of Medicine and New York University Langone Hospitals — New York, New York
  • The University of North Carolina at Chapel Hill — Chapel Hill, North Carolina
  • Avera Cancer Institute — Sioux Falls, South Dakota
  • Swedish Cancer Institute Medical Oncology — Seattle, Washington
  • West Virginia University Health Sciences Center — Morgantown, West Virginia
  • Chris OBrien Lifehouse — Camperdown, New South Wales
  • Universitair Ziekenhuis Antwerpen — Edegem,
  • Algemeen Ziekenhuis Maria Middelares — Ghent,
  • Jessa Ziekenhuis - Campus Virga Jesse — Hasselt,
  • AZ Delta Campus Rumbeke — Roeselare,
  • Princess Margaret Cancer Centre — Toronto, Ontario
  • CHU de Quebec Hopital de l Enfant Jesus — Québec, Quebec
  • Rigshospitalet — Copenhagen,
  • Centre Leon Berard — Lyon,
  • Centre Hospitalier Universitaire de Nantes, Hôpital Nord Laënnec — Saint-Herblain,
  • Gustave Roussy — Villejuif,
  • Universitaetsklinikum Dresden — Dresden,
  • Universitaetsklinikum Essen — Essen,
  • Universitaetsklinikum Freiburg — Freiburg im Breisgau,
  • Rambam Medical Center — Haifa,
  • Hadassah Ein-Kerem Medical Center — Jerusalem,

💰 Cost, Insurance & Patient Rights

  • 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
  • Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
  • Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Extensive Stage Small Cell Lung Cancer

Explore by condition: All Extensive Stage Small Cell Lung Cancer clinical trials

💡 How to Participate

  1. Check the checklist above to see if you may qualify.
  2. Review the official NIH record below to find the coordinating site.
  3. Ask about the visit schedule, what is covered at no cost, and any travel support.
  4. Confirm with your own doctor before making a decision.
🏛️ View Official NIH Record ↗